LSN Launches New Health Innovation Event – 4D Meets AI (September 22nd)

January 30, 2020January 30, 2020 ~ Next Phase Admin ~ Leave a comment

By Chris Kennedy, Vice President Strategic Initiatives, 4D Meets AI, LSN

chris headshot LSN is taking a strategic step forward in 2020 and introducing 4D Meets AI, a new one day conference event that will stand beside RESI Boston in September.

Artificial Intelligence (AI) is a transformative force in the healthcare industry. From hospital care to clinical research, drug development and pathology, AI applications are revolutionizing how the health sector works to reduce spending and improve patient outcomes.

The 4D Meets AI conference is organized around those early stage companies in the Drug, Device, Diagnostic and Digital Health verticals, the “4Ds”, companies that are pursuing the integration of technology, using new tools and applying methodologies that AI brings to this dynamic sector. AI will fundamentally reshape the healthcare landscape as we know it today.

LSN created the 4D Meets AI conference stemming from the success of our long-standing RESI conference series. It will continue doing what LSN does best, connecting early stage companies that develop cutting-edge AI technology in drugs, devices, diagnostics and digital health with the right investors, decision makers and thought leaders in this dynamic developing landscape.

We will launch registration soon, so stay tuned! 4D Meets AI is a unique opportunity to connect with early stage companies and investors in the healthcare AI space; if you are interested in sponsoring the event to boost your visibility, please reach out to me at c.kennedy@lifesciencenation.com.

graphic 4dai

Hot Investor Mandate: NY Private Investment Firm Invests To Lower The Cost Of Care

January 30, 2020January 30, 2020 ~ Next Phase Admin ~ Leave a comment

A private investment firm based in New York invests in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: London PE Firm Invests In Innovative Medical Services

January 30, 2020January 30, 2020 ~ Next Phase Admin ~ Leave a comment

A private equity firm based in London, UK that focuses exclusively on healthcare seeks to invest £10M-£20M over the life of an investment, but initial investment can range from £1M-£5M. Investments are most commonly in the form of equity, although there is flexibility in regards to capital structure. The firm looks to make 2-3 investments per year in revenue-generating companies.

The firm is technology and indication agnostic, but intends to focus on innovative medical products and healthcare services that aim to improve or reduce the cost of care provision, including health IT, digital health and software, primary and acute care models, homecare and social care, chronic disease management, dentistry, cosmetic and aesthetics but also medical equipment, specialty pharma, imaging, CROs and diagnostics.

There are no formal pre-requisites for company’s or management teams in terms of level of experience. The firm will consider companies with products in the clinic as long as the company has at least one product that is on the market. The firm prefers to invest in companies who are headquartered or have a large presence in Europe. U.S.-based companies with a European angle will also be considered.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Asia Family Office-Backed Firm Invests in Life Science Platforms

January 30, 2020January 30, 2020 ~ Next Phase Admin ~ Leave a comment

A biotech early stage investment fund founded in 2016 and headquartered in Taipei, Taiwan invests from an Evergreen Fund backed by a Family Office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Transatlantic Venture Firm Invests Opportunistically In Medtech And Digital Health

January 30, 2020January 30, 2020 ~ Next Phase Admin ~ Leave a comment

A transatlantic investment firm based in the Netherlands with an additional operation in Boston, USA, is investing from a fund of over $250 million. The firm prefers to invest in commercial stage diagnostics/medical technology companies. The investment size ranges from $5 million up to $30 million. The firm is seeking to make 2-3 investments over the next 6-9 months, targeting companies based in the U.S. and Europe.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices and Digital Health spaces. The firm is very opportunistic in terms of subsectors and indications. The firm does not look at therapeutics or biotech R&D service technologies. For diagnostics and medical devices, the firm is interested in companies with commercial-stage/revenue-generating products, but may also look opportunistically at earlier stage technologies. These may include 510K devices where the FDA clearance is very close and/or where reimbursement is the last hurdle and feel confident in the path to reimbursement. For digital health, the firm looks opportunistically at companies beyond the Series A stage. Historically, the firm was active in medical device companies developing orthotic and prosthetic devices, as well as peripheral vascular applications in cardiovascular diseases.

The firm focuses on investments in private companies and it will consider pre-revenue companies, depending on the opportunity. The firm prefers to invest in companies with experienced and committed management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Two Ways to Highlight Your Startup at RESI in Paris

January 23, 2020January 23, 2020 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Investor Research Analyst, LSN

On March 23^rd, RESI will be coming to Paris for our second RESI in Europe. Life Science Nation (LSN) is offering early stage companies the chance to increase their exposure through two different startup showcases – the RESI Innovation Challenge and the new Featured Company Pitch Sessions.

Those who have attended RESI in the past are familiar with the RESI Innovation Challenge, which features the 30 most ‘investable’ companies, selected after a rigorous evaluation. These companies are evaluated based on innovativeness, marketability, stage of development and competitive edge, among other criteria, with selected companies presenting posters in the exhibit hall on the day of the conference. These companies compete for ‘investments’ of ‘RESI cash’ from their fellow attendees, with the top companies receiving prizes at the end of the day. Investors who attend RESI regularly are aware that companies selected to participate in the Innovation Challenge are selected based on merit, and many Innovation Challenge winners have successfully raised investments. The application deadline for the Innovation Challenge is February 21^st, so make sure to apply here!

Meanwhile, the Featured Company Pitch Sessions are a new opportunity for companies to gain exposure to the investors attending RESI. For RESI Europe, companies can pay a fee of €1000 to pitch to a panel of investor judges as well as a broader audience of RESI attendees. Each hour slot will feature 4 companies pitching, with time after every pitch reserved for questions from the panel and audience. The application for the Featured Company Pitch Session is streamlined, with a rolling acceptance process. Pitching spots can fill up fast, so make sure to apply early.

Companies participating in both the Innovation Challenge and the Featured Company Pitch Sessions will be featured in the LSN Newsletter and the RESI Program Guide, with the Innovation Challenge winners announced after RESI.

RESI Innovation Challenge	Featured Company Pitch Sessions
Rigorous application process, top 30 selected	Streamlined application process, rolling acceptance
Poster display in the exhibit hall	Pitch slot with 4 min pitch and 8 min Q&A
Competition with prizes	Pitch to a dedicated feedback panel of investors
No fee to participate (beyond registration)	Additional fee of €1000

Focus on Europe

January 23, 2020January 28, 2020 ~ Next Phase Admin ~ Leave a comment

By Gregory Mannix, Vice President International Business Development, LSN

At Life Science Nation we think that a strong and interconnected global ecosystem of life science strategic partners, investors and service providers will benefit the myriad entrepreneurs from around the globe in their quest to develop the latest technologies to treat and cure diseases. The fact that we took the Redefining Early Stage Investment (RESI) conference to Europe and Asia in 2019—for the first time outside of North America—is testament to this commitment.

Expanding the ecosystem to distant continents from our home base in Boston is a considerable challenge, but we think it’s worth it. We are making an effort to augment our contacts with major technology hubs in Europe and Asia in order to facilitate their emerging technologies joining the global ecosystem and accelerate their pathways to success.

In this context, LSN will be offering Fundraising Bootcamps in multiple cities in Europe in February. They are a chance for early-stage companies to learn about the fundraising ecosystem and the importance of honing their messaging to get the most traction with important partners. We hope you will be able to join us at one of our events. We would love to meet you!